Compare Heron Therapeutics Inc (HRTX) vs Solaris Energy Infrastructure Inc. Class A Common Stock (SEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Solaris Energy Infrastructure Inc. Class A Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.18M), while Solaris Energy Infrastructure Inc. Class A Common Stock trades at $68.5 (market cap $5.12B). The key difference: Solaris Energy Infrastructure Inc. Class A Common Stock is far larger — about 69× Heron Therapeutics Inc's market cap, and Solaris Energy Infrastructure Inc. Class A Common Stock pays a 0.62% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and Solaris Energy Infrastructure Inc. Class A Common Stock for 0 Days on average.
| HRTX | SEI | |
|---|---|---|
Market Cap | $74.18M | $5.12B |
Volume | 1,857,401 | 2,532,496 |
Sector | Health | Energy |
52-Week High | $1.49 | $82.88 |
52-Week Low | $0.27 | $40.64 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $180.92M | $6.81B |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
SEI (Solaris Energy Infrastructure) trades at $77.83, down 1.83% today, but maintains strong analyst support with 9 unanimous buy ratings and a $100.56 consensus price target. The stock shows positive momentum with three consecutive quarterly earnings beats and projected revenue growth from $622M in 2025 to $762M in 2026. Recent technical analysis indicates neutral signals with support at $76 and resistance at $79.
The outlook remains positive given strong earnings performance and expansion initiatives, though elevated valuation ratios (P/E of 98.52) and significant debt issuance ($1.25B notes) present risks. The upcoming Q3 2026 earnings report on October 21 will be crucial for validating growth trajectory amid energy sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Solaris Energy Infrastructure Inc. Class A Common Stock
Solaris Energy Infrastructure, Inc. provides mobile power generation, control, and distribution equipment and logistics equipment for managing raw materials at well sites, operating through its Solaris Power Solutions and Solaris Logistics Solutions segments for data center, energy, commercial, and industrial customers.
Read more on SEI →
